Expert Opinion on Drug Safety [ISSN 1474-0338]; [e- ISSN 1744-764X] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles on all aspects of drug safety, as well as original papers on the clinical implications of drug treatment safety issues.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Drug Safety aims to address the needs of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.

The journal welcomes:

    Reviews covering occurrence, management and prevention of drug-associated adverse events
    Reviews covering risk-benefit analyses of individual drugs and drug classes
    Reviews covering safety in 'at-risk' patient populations
    Reviews covering comparative tolerability studies
    Reviews covering pharmacovigilance and pharmacoepidemiological studies
    Drug safety evaluations reviewing the safety data on a specific drug
    Original research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes
    Original research papers on methods for the detection and evaluation of drug-associated adverse events

Please note that the journal does not publish case reports or animal studies. Letters to the Editor should discuss articles previously published in the journal.

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results.

Article Highlights – an executive summary of the author’s most critical points.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Drug Safety, part of the Expert Collection brand.

EDITOR IN CHIEF 

Roger McIntyre: University of Toronto, Canada
EDITORIAL ADVISORY BOARD 

Bernard Bannwarth: Hopital Pellegrin, France 
Leslie Citrome: New York Medical College, Valhalla, NY, USA  
Barton Cobert: Medidata Solutions Worldwide, USA 
Judith Currier: David Geffen School of Medicine at UCLA, USA 
Moses Elisaf: University of Ioannina, Greece 
Roy Fleischmann: Radiant Research, USA 
Vittorio Gebbia: University of Palermo, Italy 
Peter Giannoudis: University of Leeds, UK 
Joerg Hasford: Ludwig-Maximilians University, Germany 
Stephen Holgate: Southampton General Hospital, UK 
Neal Kleiman: Methodist DeBakey Heart Center, USA 
Rupert Leong: University of New South Wales, Australia 
Hubert GM Leufkens: Utrecht University, Netherlands 
Giuseppe Mancia: University of Milano-Bicocca, Italy 
Nicholas Moore: Hopital Pellegrin, France 
Munir Pirmohamed: University of Liverpool, UK 
Jürgen K Rockstroh: University of Bonn, Germany 
Eleftherios Tsiridis: Aristotle University Medical School, Greece